Medtronic (MDT) Tops Q2 EPS by 8c, Reiterates Guidance

Medtronic, Inc. (MDT) PT Raised to $99 at Jefferies; Q2 Eases Growth Concerns

Jefferies raised its price target on Medtronic, Inc. (NYSE: MDT) to $99.00 (from $96.00) while maintaining a Buy rating following Q2 results.

Analyst Raj Denhoy said the results eased concerns of a slowing growth trajectory.

"Despite weather impacts, F18 guidance for +4-5% sales and... More

Medtronic, Inc. (MDT) PT Raised to $86 at Wells Fargo on 2Q Report; 'Better gross Margin Than Modeled'

Wells Fargo raised its price target on Medtronic, Inc. (NYSE: MDT) to $86.00 (from $83.00) while maintaining a Market Perform rating, following the company's second quarter earnings report.

Analyst Larry Biegelsen notes a positive outlook on the shares, as the company reported second quarter... More

Medtronic, Inc. (MDT) PT Raised to $88 at Leerink Partners, Gorwth Should Accelerate in H2 2018

Leerink Partners raised its price target on Medtronic, Inc. (NYSE: MDT) to $88.00 (from $85.00) while maintaining a Market Perform rating.

Medtronic, Inc. (MDT) PT Raised to $85 at Stifel

Stifel raised its price target on Medtronic, Inc. (NYSE: MDT) to $85.00 (from $83.00) while maintaining a Hold rating.

Medtronic, Inc. (MDT) PT Raised to $94 at Barclays

Barclays raised its price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $90.00) while maintaining a Overweight rating.

Analyst Matt Taylor remains positive on the equity citing anticipation for improving product cycles and Diabetes recovery which could boost revenue growth in H2 2018 and... More

Medtronic, Inc. (MDT) PT Bumped to $95 at Needham & Company

Needham & Company analyst Mike Matson bumped his price target on Medtronic, Inc. (NYSE: MDT) to $95.00 (from $94.00) while maintaining a Buy rating following Q1 results that beat the Street and reiterated guidance.

Matson notes organic revenue growth improved to 4.0% (excluding Hurricane Maria)... More